ANJESO Drug Patent Profile

Which patents cover Anjeso, and what generic alternatives are available?

Anjeso is a drug marketed by Baudax and is included in one NDA. There are five patents protecting this drug.

This drug has forty-seven patent family members in thirteen countries.

The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Anjeso

A generic version of ANJESO was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for ANJESO

International Patents:	47
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	145
Clinical Trials:	1
Patent Applications:	2,542
Drug Prices:	Drug price information for ANJESO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ANJESO
What excipients (inactive ingredients) are in ANJESO?	ANJESO excipients list
DailyMed Link:	ANJESO at DailyMed

See drug prices for ANJESO

Recent Clinical Trials for ANJESO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yangtze River Pharmaceutical Group Co., Ltd.	PHASE1

See all ANJESO clinical trials

US Patents and Regulatory Information for ANJESO

ANJESO is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No			Y
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No			Y

Expired US Patents for ANJESO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020

EU/EMA Drug Approvals for ANJESO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02
Boehringer Ingelheim Vetmedica GmbH	Metacam	meloxicam	EMEA/V/C/000033Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.	Authorised	no	no	no	1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited	Rheumocam	meloxicam	EMEA/V/C/000121DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.	Authorised	yes	no	no	2008-01-10
Emdoka bvba	Emdocam	meloxicam	EMEA/V/C/002283CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.	Authorised	yes	no	no	2011-08-18

International Patents for ANJESO

See the table below for patents covering ANJESO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	431131
Canada	2517679	FORMULATIONS DE MELOXICANE NANOPARTICULAIRES (NANOPARTICULATE MELOXICAM FORMULATIONS)
Germany	602004021107
Denmark	3090731
Denmark	3434261
European Patent Office	1617816	FORMULATIONS DE MELOXICANE NANOPARTICULAIRES (NANOPARTICULATE MELOXICAN FORMULATIONS)
European Patent Office	1938803	Formules à méloxicane nanoparticulaire (Formulations comprising nanoparticulate meloxican)

Market Dynamics and Financial Trajectory for Anjeso

Last updated: February 20, 2026

What is Anjeso?

Anjeso (generic: meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) developed by Navya Pharmaceuticals. It is indicated for the management of moderate to severe pain in adult patients, primarily in post-surgical settings.

Regulatory Status and Approval Timelines

• FDA Approval: Anjeso received FDA approval on February 24, 2023.
• Marketing Authorization: It is marketed as a continuous, injectable formulation for acute pain management where rapid onset and sustained effect are required.
• European Market: Not yet approved by the European Medicines Agency (EMA); approval expected in 2024 pending regulatory review.

Market Size and Key Drivers

Global NSAID Market

• Market Value (2023): Estimated at USD 15.4 billion.
• Expected Growth (2023-2028): Compound annual growth rate (CAGR) of approximately 4.3%[1].

Specific Pain Management Segment

• Postoperative Pain: A major segment, with an estimated value of USD 5.2 billion globally.
• Growth Factors: Rising surgical procedures, opioid reduction initiatives, and demand for non-opioid analgesics.

Anjeso’s Target Market

• Acute pain management in hospitals and outpatient clinics.
• Post-surgical analgesia, especially in settings emphasizing opioid sparing.

Competitive Landscape

Existing Intravenous NSAIDs

Drug	Formulation	Market Share	Year of FDA Approval	Notable Features
Solu-Medrol	Injectable corticosteroid	Dominates regional pain clinics	1950s (not NSAID)	Long-established, broad indications
Toradol (ketorolac)	Injectable NSAID	Significant in acute setting	1989	Potent analgesic, limited to 5-day use due to renal risks
Diclofenac	Injectable formulations	Limited compared to oral	2020 (new formulations)	Widely used for various pain types

Anjeso Differentiation

• Formulation: Extended-release IV meloxicam.
• Advantages: Onset within 30 minutes, sustained effect over 24 hours, opioid-sparing potential.
• Target niches: Postoperative care, emergency departments, outpatient surgical procedures.

Financial Trajectory: Revenue Projections and Pricing

Pricing Strategy

• Per Dose Cost: Approximate USD 45–60 per administration, based on comparator NSAIDs (e.g., ketorolac USD 25–30 per dose).
• Market Penetration: Targeting hospitals’ formularies initially, expanding to outpatient clinics.

Revenue Estimates

Year	Assumed Market Penetration	Estimated Units Sold	Gross Revenue (USD millions)
2023	1% of target market	100,000 doses	4.5 – 6 million
2024	5% of target market	500,000 doses	22.5 – 30 million
2025	10% of target market	1 million doses	45 – 60 million

Note: These estimates depend on hospital adoption rates, insurance reimbursements, and competitive dynamics.

Key Market Risks

• Pricing pressures from existing generic NSAIDs.
• Regulatory hurdles delaying broader approvals outside the U.S.
• Clinical efficacy and safety profile relative to competitors.
• Adoption resistance from clinicians accustomed to existing NSAIDs.

Market Entry and Growth Strategies

• Partnerships: Collaborate with hospital groups and pain management clinics.
• Differentiation: Emphasize rapid onset and opioid-sparing benefits.
• Pricing: Competitive with existing injectable NSAIDs to accelerate adoption.
• Clinical Data: Generate real-world evidence to support efficacy and safety claims.

Regulatory Outlook and Pathways

• Continue expanding approvals in European Union, Asia, and other markets.
• Explore broader indications such as rheumatoid arthritis if supported by data.

Conclusion

Anjeso’s market prospects depend on its ability to capitalize on acute pain management needs, particularly in opioid-sparing protocols. Its financial trajectory can reach USD 60 million in initial years post-launch, scaling with hospital adoption and geographic expansion.

Key Takeaways

• Anjeso is a intravenously administered NSAID approved by the FDA in 2023.
• The global NSAID market, valued at USD 15.4 billion in 2023, drives demand.
• Revenue projections suggest USD 20–60 million within the first two years, conditional on market uptake.
• Competition from existing IV NSAIDs requires strategic differentiation and pricing.
• Regulatory expansion outside the U.S. could significantly increase market potential.

FAQs

1. When did Anjeso receive FDA approval?

Anjeso was approved by the FDA on February 24, 2023.

2. What are the main advantages of Anjeso over existing NSAIDs?

It offers rapid onset within 30 minutes and sustained analgesic effect, with potential opioid reduction benefits.

3. What is the size of the target market for Anjeso?

The global post-operative pain segment is valued around USD 5.2 billion, with broader NSAID market at USD 15.4 billion.

4. How does pricing compare to competitors?

Estimated per-dose cost is USD 45–60, somewhat higher than ketorolac but justified by extended efficacy and opioid-sparing benefits.

5. What are the primary risks for Anjeso’s market success?

Pricing pressures, regulatory delays, clinical safety concerns, and clinician adoption resistance.

References

1. Grand View Research. (2023). NSAID Market Size, Share & Trends Analysis Report.[1]